BioCryst Pharmaceuticals BCRX License and other revenues — Total trade receivables

Similar metrics at other companies

CSTMTrade receivables and other, net

$723M+48.8%

CHDNTrade receivables — Accounts receivable

$33M-9.1%

PEPTrade receivables

$9.27B+9.2%

CSTMTrade receivables and other, net

$33M-13.2%

CHDNOther receivables — Accounts receivable

$31M+15.7%

OTISTrade receivables and unbilled receivables

$3.7B+8.8%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNet.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's license and other revenues — total trade receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's license and other revenues — total trade receivables?: BioCryst Pharmaceuticals (BCRX) reported license and other revenues — total trade receivables of $6.6M in Q1 2026.
What does license and other revenues — total trade receivables mean?: This metric measures the total outstanding amounts owed to the company by customers or partners for services rendered or licenses granted within the specific segment. It represents the value of credit extended to counterparties that has not yet been collected in cash. High levels of trade receivables relative to revenue may indicate potential collection risks or changes in payment terms with strategic partners.